Ensign Peak Advisors, Inc Enanta Pharmaceuticals Inc Transaction History

Ensign Peak Advisors, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$11.09 - $22.13 $53,232 - $106,224	4,800 Added 31.07%	20,250 $226,000
Q1 2023 May 15, 2023	BUY	$38.82 - $54.59 $9,705 - $13,647	250 Added 1.64%	15,450 $624,000
Q4 2022 Feb 13, 2023	SELL	$40.77 - $53.73 $818,253 - $1.08 Million	-20,070 Reduced 56.9%	15,200 $707,000
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $57,271 - $84,526	1,186 Added 3.48%	35,270 $1.83 Million
Q2 2022 Aug 12, 2022	SELL	$38.13 - $76.93 $152,939 - $308,566	-4,011 Reduced 10.53%	34,084 $1.61 Million
Q4 2021 Feb 11, 2022	BUY	$60.19 - $97.37 $1.03 Million - $1.67 Million	17,195 Added 82.27%	38,095 $2.85 Million
Q2 2021 Aug 13, 2021	BUY	$43.76 - $53.11 $21,880 - $26,555	500 Added 2.45%	20,900 $920,000
Q1 2021 May 12, 2021	BUY	$41.69 - $54.95 $145,915 - $192,325	3,500 Added 20.71%	20,400 $1.01 Million
Q1 2020 May 11, 2020	BUY	$40.22 - $62.0 $80,440 - $124,000	2,000 Added 13.42%	16,900 $869,000
Q4 2019 Feb 14, 2020	BUY	$57.95 - $66.61 $863,455 - $992,489	14,900 New	14,900 $921,000

107

21.2M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $102M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.